Ann: PharmAust to Evaluate Monepantel on COVID-19, page-312

NZ Trader said words to effect a while ago that maybe MPL will be used with another drug to fight CV.
I decided to look at that .

Now we all know that the mTOR inhibitor Rapamycin disrupts binding of LARP1 to mTORC1 and has been shown to to reduce infection of CV . This new study shows reduction of infection rate of 60% in vitro. Which is possibly very good for MPL.

Reference A SARS-COV-2 Human protein interaction map reveals drug targets and potential re drug purposing . Gordon et al 2020.

CV patients who seem at risk have co morbidities of Hypertension which seemingly increases rates of acute serious infection.

CV uses ACE2 receptors to gain entry into our target cells. We all should know that !

Some current CV studies are looking at down regulating ACE2 using Lorsatan
a common drug kept by our local pharmacy with hope this will inhibit CV migration by inhibition of ACE2 receptors reducing pulmonary complications from CV.

Trick is we may need two drugs that have completed human phase 1 trials to give a double punch to this virulent bug.

My quinella at the moment is MPL and Losartan ( they have been studying this drug as an anti viral replication antagonist since (2002) .

Have no doubt people we are on a good Company PharmAust. !